Lifeward Granted Temporary Nasdaq Delisting Extension

Medical device maker misses compliance deadline but gets 180 more days to regain $1 minimum share price

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Lifeward, a Marlborough-based medical device manufacturer, has been granted a temporary extension by Nasdaq to avoid delisting after failing to meet the $1 minimum bid price requirement. The company received a deficiency letter in August 2025 and was given until February 2026 to regain compliance, but was unable to do so. Nasdaq has now granted Lifeward an additional 180 days, until August 2026, to achieve the minimum bid price for 10 consecutive business days.

Why it matters

Lifeward's potential Nasdaq delisting highlights the challenges facing small-cap medical device companies to maintain listing requirements amid market volatility. The extension buys Lifeward more time to execute a turnaround strategy, including a potential 1-for-12 reverse stock split, and complete a transformative deal with Oramed Pharmaceuticals to bolster its financial position.

The details

Lifeward received the initial Nasdaq deficiency letter on August 5, 2025 due to its inability to meet the $1 minimum bid price requirement for 30 consecutive business days. The company was given until February 2, 2026 to regain compliance, but failed to do so. As a result, Nasdaq granted Lifeward an additional 180 calendar days, until August 3, 2026, to achieve the minimum bid price for 10 consecutive business days and avoid delisting.

  • Lifeward received its Nasdaq deficiency letter on August 5, 2025.
  • Lifeward had until February 2, 2026 to regain compliance with the $1 minimum bid price.
  • Nasdaq granted Lifeward an additional 180 calendar days, until August 3, 2026, to achieve the minimum bid price.

The players

Lifeward

A medical device manufacturer based in Marlborough, Massachusetts that is at risk of being delisted from the Nasdaq stock exchange.

Nasdaq

The stock exchange that issued Lifeward a deficiency letter and is granting the company a temporary extension to avoid delisting.

Oramed Pharmaceuticals

A New York City-based pharmaceutical company that has agreed to purchase nearly 50% of Lifeward in exchange for its protein oral delivery technology to treat diabetes.

Almog Adar

The Chief Financial Officer of Lifeward.

Got photos? Submit your photos here. ›

What they’re saying

“We believe that in the next…180 days, the company will achieve the dollar target and will be in compliance again with the NASDAQ.”

— Almog Adar, CFO, Lifeward (Worcester Business Journal)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Lifeward's potential Nasdaq delisting highlights the challenges facing small-cap medical device companies to maintain listing requirements amid market volatility. The extension buys Lifeward more time to execute a turnaround strategy, including a potential reverse stock split, and complete a transformative deal to bolster its financial position.